Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 20/20 | 1.00 |
| ▸ | SCN7A | Q01118 | 1/20 | 1.00 |
| ▸ | SCN5A | Q14524 | 1/20 | 1.00 |
| ▸ | SCN2A | Q99250 | 1/20 | 1.00 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 1.00 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Funapide SCHEMBL29379143 | 1.00 | SCN9A (1.00) | SCN9ASCN7ASCN5ASCN2ASCN8A | |
| Funapide SCHEMBL281394 | 1.00 | SCN9A (1.00) | SCN9ASCN7ASCN5ASCN2ASCN8A | |
| Funapide SCHEMBL1612874 | 1.00 | SCN9A (1.00) | SCN9ASCN7ASCN5ASCN2ASCN8A | |
| SCHEMBL12712202 | 0.94 | SCN9A (0.89) | SCN9ASCN7ASCN5ASCN2ASCN8A | |
| SCHEMBL2309587 | 0.94 | SCN9A (0.89) | SCN9ASCN7ASCN5ASCN2ASCN8A | |
| SCHEMBL2305585 | 0.94 | SCN9A (0.89) | SCN9ASCN7ASCN5ASCN2ASCN8A | |
| SCHEMBL3329910 | 0.93 | SCN9A (0.86) | SCN9ASCN7ASCN5ASCN2ASCN8A | |
| SCHEMBL2303448 | 0.91 | SCN9A (0.83) | SCN9ASCN7ASCN5ASCN2ASCN8A | |
| SCHEMBL3331247 | 0.90 | SCN9A (0.82) | SCN9ASCN7ASCN5ASCN2ASCN8A | |
| SCHEMBL4730724 | 0.90 | SCN9A (0.81) | SCN9ASCN7ASCN5ASCN2ASCN8A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 112 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11162104-B2 | SCN9A antisense pain killer | OLIPASS CORPORATION (KR) | 2021-11-02 | — | — | US | disclosed |
| US-20200109151-A1 | SOLID STATE FORMS OF SPIRO-OXINDOLE COMPOUNDS | FLEXION THERAPEUTICS, INC. | 2020-04-09 | — | — | US | disclosed |
| US-20200109151-A1 | SOLID STATE FORMS OF SPIRO-OXINDOLE COMPOUNDS | FLEXION THERAPEUTICS, INC. | 2020-04-09 | — | — | US | disclosed |
| US-20190218255-A1 | SCN9A ANTISENSE OLIGONUCLEOTIDES | OLIPASS CORPORATION (KR) | 2019-07-18 | — | — | US | disclosed |
| US-20190071449-A1 | SOLID STATE FORMS OF SPIRO-OXINDOLE COMPOUNDS | PACIRA CRYOTECH, INC. | 2019-03-07 | — | — | US | disclosed |
| US-20190071449-A1 | SOLID STATE FORMS OF SPIRO-OXINDOLE COMPOUNDS | PACIRA CRYOTECH, INC. | 2019-03-07 | — | — | US | disclosed |
| EP-2838902-B1 | ASYMMETRIC SYNTHESES FOR SPIRO-OXINDOLE COMPOUNDS USEFUL AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC (CA) | 2018-12-05 | — | — | EP | disclosed |
| US-10100060-B2 | Asymmetric synthesis of funapide | XENON PHARMACEUTICALS INC. (CA) | 2018-10-16 | — | — | US | disclosed |
| WO-2018051175-A1 | SCN9A ANTISENSE OLIGONUCLEOTIDES | OLIPASS CORPORATION (KR) | 2018-03-22 | — | — | WO | disclosed |
| US-20180016283-A1 | SOLID STATE FORMS OF SPIRO-OXINDOLE COMPOUNDS | PACIRA CRYOTECH, INC. | 2018-01-18 | — | — | US | disclosed |
| WO-2011047173-A2 | PHARMACEUTICAL COMPOSITIONS FOR ORAL ADMINISTRATION | XENON PHARMACEUTICALS INC. (CA) | 2011-04-21 | — | — | WO | disclosed |
| US-20110086899-A1 | PHARMACEUTICAL COMPOSITIONS FOR ORAL ADMINISTRATION | XENON PHARMACEUTICALS INC. (CA) | 2011-04-14 | — | — | US | disclosed |
| US-20110086899-A1 | PHARMACEUTICAL COMPOSITIONS FOR ORAL ADMINISTRATION | XENON PHARMACEUTICALS INC. (CA) | 2011-04-14 | — | — | US | disclosed |
| US-20110087027-A1 | SYNTHETIC METHODS FOR SPIRO-OXINDOLE COMPOUNDS | XENON PHARMACEUTICALS INC. (CA) | 2011-04-14 | — | — | US | disclosed |
| US-20110087027-A1 | SYNTHETIC METHODS FOR SPIRO-OXINDOLE COMPOUNDS | XENON PHARMACEUTICALS INC. (CA) | 2011-04-14 | — | — | US | disclosed |
| US-20110087027-A1 | SYNTHETIC METHODS FOR SPIRO-OXINDOLE COMPOUNDS | XENON PHARMACEUTICALS INC. (CA) | 2011-04-14 | — | — | US | disclosed |
| WO-2011002708-A1 | ENANTIOMERS OF SPIRO-OXINDOLE COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2011-01-06 | — | — | WO | disclosed |
| US-20100331386-A1 | ENANTIOMERS OF SPIRO-OXINDOLE COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2010-12-30 | — | — | US | disclosed |
| US-20100331386-A1 | ENANTIOMERS OF SPIRO-OXINDOLE COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2010-12-30 | — | — | US | disclosed |
| US-20100331386-A1 | ENANTIOMERS OF SPIRO-OXINDOLE COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2010-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180016283-A1 | SOLID STATE FORMS OF SPIRO-OXINDOLE COMPOUNDS | OXTR, CFAP410, NR3C2 | SCN9A 1533/4885SCN7A 658/4885SCN5A 1452/4885 |
| US-20110087027-A1 | SYNTHETIC METHODS FOR SPIRO-OXINDOLE COMPOUNDS | TRPV1, TRPV5, TRPV3 | SCN9A 47/4885SCN7A 44/4885SCN5A 15/4885 |
| US-10100060-B2 | Asymmetric synthesis of funapide | SCN2A, SCN10A, SCN1A | SCN9A 42/4885SCN7A 4/4885SCN5A 71/4885 |
| US-20110086899-A1 | PHARMACEUTICAL COMPOSITIONS FOR ORAL ADMINISTRATION | TRPV1, SCN5A, TRPV5 | SCN9A 34/4885SCN7A 18/4885SCN5A 2/4885 |
| US-20190218255-A1 | SCN9A ANTISENSE OLIGONUCLEOTIDES | SCN9A, SCN7A, SCN8A | SCN9A 1/4885SCN7A 2/4885SCN5A 9/4885 |
| US-20200109151-A1 | SOLID STATE FORMS OF SPIRO-OXINDOLE COMPOUNDS | OXTR, CFAP410, NR3C2 | SCN9A 1533/4885SCN7A 658/4885SCN5A 1452/4885 |
| US-20190071449-A1 | SOLID STATE FORMS OF SPIRO-OXINDOLE COMPOUNDS | OXTR, CFAP410, NR3C2 | SCN9A 1533/4885SCN7A 658/4885SCN5A 1452/4885 |
| US-20100331386-A1 | ENANTIOMERS OF SPIRO-OXINDOLE COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS | TRPV1, TRPV5, TRPV3 | SCN9A 21/4885SCN7A 20/4885SCN5A 14/4885 |
| US-11162104-B2 | SCN9A antisense pain killer | SCN9A, SCN7A, SCN8A | SCN9A 1/4885SCN7A 2/4885SCN5A 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.